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Abstract
Objective. To evaluate the diagnostic yield of MRI performed for characterization of focal hepatic lesions that are interpreted
as indeterminate on CT. Patients and methods. In a retrospective investigation, 124 indeterminate focal hepatic lesions in 96
patients were identified on CT examinations over 5 years from 1997 to 2001. All patients had MRI performed for the liver
within 6 weeks of their CT examination. CT and MR images were reviewed independently by two separate groups of two
radiologists. The value of MRI in characterizing these lesions was assessed. Diagnoses were confirmed based on histology,
characteristic imaging features, and clinical follow-up. Results. MRI definitely characterized 73 lesions (58%) that were
indeterminate on CT. MRI was accurate in 72/73 of these lesions. MRI could not definitely characterize 51 lesions (42%).
Ten lesions were not visualized on MRI, and follow-up imaging confirmed that no lesion was present in eight of these cases
(pseudolesions). Conclusion. MRI is valuable for the characterization of indeterminate focal hepatic lesions detected on CT.
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Introduction
MRI is frequently used as a problem-solving techni-
que for the evaluation of focal hepatic lesions that are
deemed indeterminate with other imaging modalities.
Such evaluation can be challenging, particularly in
patients with a history of malignancy or in those with
underlying liver disease, such as cirrhosis, that carry
an increased risk for cancer.
The performance of specific MR sequences and
particular imaging signs and signal characteristics
for the assessment of focal hepatic lesions have
been evaluated in many previous studies [134].
For example, the value of T2-weighted [1,2,57,13,
21,23,24,27,28] and gadolinium-enhanced MRI for
the depiction and characterization of liver lesions
[2,3,812,1421,2932], as well as the significance
of various enhancement patterns for the diagnosis of
benign and malignant liver lesions [17,19,20,24,31]
have been described.
The specific aim of our study was to explore the
effectiveness, and hence the clinical utility, of MR
characterization of focal hepatic lesions in patients
referred for further work up of CT-indeterminate
lesions in a routine, university-based, clinical setting
over a 5-year period.
Patients and methods
Patients
MRI scans of 124 CT-indeterminate focal hepatic
lesions in 98 patients (46 men and 52 women)
obtained from January 1997 to December 2001
were analyzed retrospectively. A lesion was considered
indeterminate when, based on the official CT report,
a definitive diagnosis was not given and language
such as ‘indeterminate’ or ‘cannot be characterized’
was used. Lesions for which MRI was recommended
for further characterization were also considered
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indeterminate. The mean patient age was 57.7 years
(range 2091 years). The indications for CT scans
were varied and included abdominal pain, mass,
jaundice, further investigation of hepatic lesion de-
tected on ultrasound, follow-up of liver diseases
(hepatitis, cirrhosis, and hemochromatosis) or pri-
mary extrahepatic malignancy to search for metas-
tases.
The inclusion criteria were: (1) MRI examination
performed within 6 weeks after a non-diagnostic CT
scan for focal hepatic lesion(s); (2) lack of therapeutic
intervention in the interim such as surgery, RF
ablation, aspiration or chemo-embolization; and (3)
subsequent verification of the lesion type by histology,
surgery, clinical follow-up, or cross-sectional imaging
follow-up.
Of a total of 191 focal hepatic lesions identified in
149 patients, only 98 patients with 124 hepatic lesions
met all the eligibility criteria and were included in this
study. The size of the lesions ranged from 3 to 74 mm
(mean 24 mm); 24 lesions in 19 patients were smaller
than 10 mm.
CT and MRI
CT examinations were performed (Somatom plus and
volume zoom or Somatom sensation 16, Erlangen,
Germany), using portal venous phase scans (n101),
triple phase scans (n19), and non-contrast scans in
four cases (two cases because of allergy and two
because of debilitated condition).
MRI was performed on one of two 1.5 Tesla
systems (Magnetom Symphony, Siemens Medical
Systems, Erlangen, Germany or Signa, General Elec-
tric Medical Systems, Milwaukee, WI, USA), with
high-performance gradients (maximum gradient
strength, 25 mT/m; rise time, 600 ms) and a phased
array torso coil. Implemented pulse sequences con-
sisted of T1-weighted in-phase (TR/TE150/4.2)
and opposed-phase (TR/TE150/2.1) gradient
echo (when using simultaneous in/opposed phase
sequence, TR160 and TE5.3 for the in-phase
and 2.7 for the opposed phase), HASTE (half-Fourier
acquisition single-shot turbo SE, TR/TE4300/64),
IR (inversion recovery, TR/TE3600/76120,
ETL33), or FSE (breath-hold TR3140/TE
101, ETL29, or non-breath-hold TR3000,
TE8090, and ETL78).
The axial T1-weighted dynamic gadolinium-en-
hanced imaging performed in the early study period
(January 1997 to December 1999) was performed
using a two-dimensional (n56) spoiled gradient-
echo sequence with fat suppression (B200/1.2; slice
thickness; 68 mm with no inter-slice gap; matrix,
512160; breath-hold, 2428 s). Dynamic gadoli-
nium-enhanced imaging performed in the later period
(January 2000 to December 2001) was a three-
dimensional (n67) axial spoiled gradient-echo se-
quence with fat suppression (TR range/TE range, 4-6/
1-2; flip angle, 128; section thickness, 34 mm with
zero interpolation yielding an effective section thick-
ness of 1.52 mm; matrix, 320160; breath-hold,
2428 s).
Gadolinium-enhanced imaging was performed in
the arterial dominant, portal venous, and 2- and
5-min delayed phases of enhancement. The contrast
agent was administered via a 20 or 22 gauge venous
catheter placed in the antecubital fossa and attached
to an MR-compatible power injector (Spectris;
Medrad, Pittsburgh, PA, USA). All patients received
a bolus injection of 0.1 mmol/kg of gadopentetate
dimeglumine (Magnevist; Berlex Laboratories,
Wayne, NJ, USA) at a rate of 2 ml/s followed by
15 ml/s of saline flush at the same rate. In the earlier
studies (November 1998 to December 1999), the
arterial phase imaging was performed with a fixed
delay of 15 s after gadolinium injection. In the later
studies (January 2000 to December 2001), timing of
the arterial phase imaging was selected using auto-
mated contrast-bolus detection (Smartprep; General
Electric Medical Systems) or an arbitrary interval of
18 s between the initiation of contrast injection and
the beginning of scanning.
Verification of diagnoses
A malignant etiology was verified in 34 lesions by
histology (n30) and serial cross-sectional imaging
(n4). The latter was performed with CT (n1),
CT and MR imaging (n2), or CT and ultrasono-
graphy (n1). Criteria for the diagnosis of malig-
nancy by serial cross-sectional imaging were typical
imaging features and progressive increase in size and/
or number of lesions. The cross-sectional imaging
follow-up period for malignant lesions ranged from 24
to 86 weeks (mean 59 weeks).
A benign etiology was verified in 90 lesions by
histology (n31), intra-lesional fluid aspiration and
cytology with additional CT follow-up (n5), tagged
red blood cell nuclear scans (n7), serial cross-
sectional imaging (n41), or clinical follow-up
(n6). Serial cross-sectional imaging was performed
with CT (n16), MRI (n13), sonography (n2),
a combination of CT and MRI (n6), or a combina-
tion of CT and sonography (n4). Criteria for the
diagnosis of benign status by serial cross-sectional
imaging were stability in both the number and the size
of lesions. The serial cross-sectional imaging follow-
up period of benign lesions ranged from 46 to 194
weeks (mean98 weeks). Clinical follow-up was
defined as close medical observation of the patient
for any clinical or laboratory signs of malignant
disease; the lack of any of those signs was accepted
as proof that the lesion was benign. The clinical
follow-up period was 44182 weeks (mean98
weeks).
The initial MR imaging reports generated for
each patient were reviewed. For each eligible lesion,
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diagnostic confidence was rated using a 5-point scale:
1, definitely benign; 2, probably benign; 3, equivocal;
4, probably malignant; and 5, definitely malignant.
Lesions not detected by MRI were given a rating of 1.
Blinded readers classified each lesion under 1 of 13
possible diagnoses including cyst, hemangioma, focal
nodular hyperplasia (FNH), adenoma, focal fatty
infiltration or focal fatty sparing, infection, vascular,
traumatic, other benign, HCC, cholangiocarcinoma,
metastasis, and other malignant lesions. Inter-obser-
ver variability was tested by having two radiologists
experienced in CT and two other radiologists experi-
enced in MRI independently assess the same lesions
using the same 5-point scale under standardized
conditions (i.e. unaware of the initial interpretations,
patient history, or clinical records).The CT and MR
interpreters were fellowship-trained in body CT and
MR imaging and had 45 years of experience in CT
and MR imaging of the liver. The complete CT and
MR imaging data sets were made available to each
interpreter either on hard-copy films for studies
performed before 2000 or on a PACS workstation
(Siemens MV 1000, Siemens Medical Solutions,
Erlangen, Germany) for more recent studies.
Statistical analysis
All statistical calculations and analyses were per-
formed by a biostatistician at our institution. The
data were analyzed with descriptive statistics. Con-
tingency tables were constructed comparing the
diagnoses from CT with those from MRI. As there
were four readers (two CT readers and two MRI
readers) who interpreted the scans independently,
comparisons were made on the basis of calculated
percentages rather than raw numbers. An average of
four comparisons was calculated for each patient.
Because different readers were used for CT and MR,
each MR reader had to be compared to two other CT
readers. Agreement between the two CT interpreters
and between MRI interpretations was determined
using weighted kappa statistics [35].
Results
A total of 124 lesions were found in 98 patients on the
CT examinations. The indeterminate nature of the
lesions was confirmed by blinded CT readers and
all lesions underwent further examination with
MRI within 6 weeks after CT examination. MR
readers were able to definitively characterize 73
lesions based on MR lesion characteristics and were
accurate in 72 of these lesions (58% of the total
number of CT-indeterminate lesions). The lesion was
considered definitely characterized only when both
MR readers agreed. Representative images are shown
in Figures 13.
One lesion was interpreted by both MRI readers as
confluent hepatic fibrosis; however, a biopsy taken
from this area showed malignant cells suggesting
hepatocellular carcinoma. Ten lesions were not visua-
lized on MRI. Follow-up examination with CT, MRI,
or both in the subsequent 4093 month period
confirmed that no lesion (pseudolesion) was present
in 8 of these 10 lesions. The other two lesions that
were missed on MRI were breast cancer metastases.
MRI readers were unable to definitively characterize
52 lesions (42%) based on MRI lesion characteristics.
For the 51 lesions not characterized by MRI, MRI
narrowed the differential diagnosis relative to CT in
31.8% of the lesions, increased the differential diag-
nosis in 36.25%, and did not change the differential
diagnosis in 31.8% of the lesions (Table I).
There was good inter-observer agreement between
the readers. For all diagnostic categories, the inter-
observer agreement was 94/124 (76%) for CT readers
(kappa0.47) and 109/124 (87%) for MR readers
(kappa0.80). With the diagnostic categories col-
lapsed into benign and malignant, the inter-observer
agreement was 105/124 (85%) for CT readers
(kappa0.50) and 114/124 (91%) for MR readers
(kappa0.81).
There were 10 lesions seen by both CT readers that
were not seen by either MR reader. Eight of these
lesions were shown to be false positive CT diagnoses
on follow-up imaging examinations. Two of the 10
lesions were shown to be false negative MR diagnoses
on the follow-up imaging examinations. Both of the
MR false negative lesions were subsequently proven to
be breast cancer metastases.
Discussion
MR imaging is commonly used as a problem-solving
imaging modality for characterization of focal liver
lesions. Although it has some advantages over CTand
ultrasonography, MRI also has some limitations. MR
image quality can be affected by patient motion and
most MR imaging protocols produce lower spatial
resolution images than CT, which can hamper visua-
lization of small lesions.
Numerous prior studies have assessed the value of
particular pulse sequences [2,1221], signal charac-
teristics [2228,33], or enhancement patterns [29
32] to better characterize focal lesions involving the
liver. The current investigation was designed to assess
the overall diagnostic yield of referring patients with
CT-indeterminate focal hepatic lesions for further
evaluation by MRI. The study design reflected our
routine clinical practice. We routinely perform multi-
phase contrast-enhanced MR examinations because it
adds diagnostic information and there is no added risk
to the patient.
The lesion types encountered in our study were
different from those described in previous studies,
particularly studies that focused mainly on distin-
guishing cysts and hemangiomas from malignan-
cies [68,10,11,1720]. We found a relatively large
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number of hemangiomas (n34), cysts (n18),
metastases (n15), HCC (n14), and FNH (n
13). We also encountered a relatively high number
of pseudolesions (n8) (Table II). The increased
frequency of pseudolesions in our patient population
is not surprising because pseudolesions often resem-
ble malignant lesions on CT [36], although in our
patient population, pseudolesions were more fre-
quently judged to be indeterminate on CT. We did
not attempt to analyze our results with respect to
subgroups of patients, but this would be a potential
topic for future investigation to determine which
subgroups (e.g. oncology patients, cirrhotics, etc.)
are most likely to benefit from MRI.
In all, 24 of 34 CT-indeterminate hemangiomas in
our study were considered to be benign by both MR
readers. The use of heavily T2-weighted images may
have contributed to this finding [5,6,25,27]. Further-
more, the selected lesions were indeterminate on
single portal venous phase contrast-enhanced CT.
Gadolinium enhancement patterns were most likely
more specific because serial post-contrast MR se-
quences were acquired, allowing for observation of the
characteristic centripetal enhancement over time.
Persistent lesion enhancement on delayed post-
contrast images may also have aided in the MR
diagnosis of hemangiomas [8,39]. The inability to
definitively characterize 29% (10/34) of hemangiomas
on MR images was due to either the small size of the
lesion or an atypical enhancement pattern [33].
Most cysts in our series were too small to char-
acterize by CT (ranging from 3 to 16 mm, mean
8.5 mm). MRI was able to definitively characterize
65% (11/18) of these cysts, which is in accordance
with earlier reports. Although T2-weighted scans were
of crucial importance for the diagnosis of hepatic
cysts, some lesions could still be confused with other
pathologies including foci of HCC and metastases
[5,13,23,28].
The seemingly low numbers of malignant lesions in
our patient population (27% of 124 lesions in all
patients); is in accordance with the literature [38,39].
Jones et al. [39] found 55 malignant lesions (22%) in
254 patients with focal hepatic lesions. The two MR
readers were able to definitely diagnose only 50%
(17/34) of all malignant lesions in our investigation.
Figure 1. Contrast-enhanced (CT, portal phase) (A, B), in-phase (C), opposed phase (D), showing indeterminate CT focal liver lesion
(arrow) that is well characterized by MRI as focal fatty infiltration (drop-off signal on opposed phase chemical shift relative to in-phase), in a
63-year-old female complaining of breast cancer, who underwent CT for assessment of presence of metastases.
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Larson et al. [34] reported a 55% diagnosis rate of
malignant focal hepatic lesions by MRI as compared
with 17% for CT.
Although differences between the initial radiology
reports and the interpreters in our study were not
significant, the CT interpreters in our study excluded
27 lesions being definitively characterized by CT; this
may be based on the fact that initial interpreters
tended to be more conservative in determining the
nature of these lesions.
The current study has some limitations. Inclusion
of more than one lesion in some patients might have
introduced a bias resulting in better observer perfor-
mance. On the other hand, the high prevalence of
Figure 2. Contrast-enhanced (CT, portal phase) (A), pre-contrast VIBE (B), arterial phase VIBE (C), portal phase (D), and T2 IR (E),
showing indeterminate CT focal liver lesion that is well characterized by MRI as hemangioma (peripheral puddling on early contrast phase,
filling up on later phase and very bright signal on T2), in a 43-year-old male.
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benign liver lesions, often coexisting in the same
patients with malignancies, may have introduced a
bias resulting in worse observer performance. For
some patients with benign lesions, only clinical follow-
up was available. We decided to include these patients
in our population because our study was designed as
an audit of our clinical work. Many of our patients,
especially those with nonmalignant findings, receive
clinical follow-up, and exclusion of those patients
would have caused selection bias that would have
entailed a higher frequency of malignant outcomes.
For those patients with clinical follow-up, the lack of
any clinical or laboratory signs of malignant disease
over a sufficiently long period of time allowed the
clinicians to make patient management decisions.
Assignment of a rating of 1 (definitely benign) to
lesions not detected on MR imaging might have
caused overestimation of the benign lesions. On the
other hand, the effect of the diagnosis ‘no lesion
detected’ on patient management is similar to the
effect of the diagnosis ‘definitely benign’. Therefore,
our categorization of these lesions approximated
clinical practice. Finally, the interpreters might have
been influenced by the presence of additional lesions,
either in the liver or in other abdominal organs.
Figure 3. Contrast-enhanced (CT, portal phase) (A), axial T2 IR (B), axial T1 in-phase (C) and contrast-enhanced VIBE (D), showing
indeterminate CT focal liver lesion (arrow) that is well characterized by MRI as simple cyst (low signal on T1 with no post contrast
enhancement and bright signal on T2).
Table I. Distribution of the lesions in the study and number well
characterized with MRI.
Diagnosis
Distribution of
the lesions
(CT-indeterminate)
Number of the
lesions correctly
well characterized
with MRI
Hemangioma 34 24
Cyst 18 11
FNH 13 6
Vascular 2 
Other benign 8 5
B1 B1
H1 H1
D2 D1
R4 R2
Infection 5 
Focal fat 2 2
HCC 14 7
Cholangiocarcinoma 4 2
Metastasis 15 8
Pseudolesion 8 8
Metastasis or HCC 1 
Total 124 72
B, biliary cystadenoma; H, hematoma; D, dysplastic nodule; R,
regenerative nodule; FNH, focal nodular hyperplasia; HCC,
hepatocellular carcinoma.
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In conclusion, this investigation provides an insight
into the current trend for the imaging work-up of focal
hepatic lesions in a large contiguous cohort of patients
over a 5-year period in a university-based radiology
practice. The results of this study highlight the clinical
utility of MRI scanning of focal hepatic lesions that
are deemed indeterminate on CT scans, and justifies
the routine referral of these patients for further
imaging prior to attempting tissue diagnosis.
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